Related Experiment Video
Updated: Mar 12, 2026
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes
Jingbo Hu1, Ping Zou2, Shuo Zhang1
1a College of Pharmaceutical Science , Zhejiang University , Hangzhou , China.
Introduction:
Most patients with type 2 diabetes, who receive monotherapy, are unable to maintain glucose levels with the progress of disease. Therefore, combination therapy with two or more anti-diabetic agents of different classes is highly desired. Sodium glucose co-transporter 2 (SGLT2) inhibitors improve glycemic control through increasing urinary glucose excretion, which is independent of β-cell function. In addition, they are generally well tolerated and associated with a low risk of hypoglycaemia. SGLT2 inhibitors as add-on therapy to metformin have an additive effect on glycemic control in patients with type 2 diabetes, and fixed-dose tablet is likely to reduce pill burden and then improve patients' adherence. Areas covered: This article reviews empagliflozin/metformin combination therapy for the treatment of type 2 diabetes. The clinical efficacy and tolerability of empagliflozin/metformin in patients with type 2 diabetes are discussed based on the available literature. Expert opinion: It was found that empagliflozin/metformin combination therapy could significantly improve glycemic control, body weight and blood pressure with a low risk of hypoglycaemia. In addition, the empagliflozin/metformin fixed-dose tablets, supported by bioequivalence studies, could reduce pill burden to further achieve the improved patients' adherence, better glycemic control and optimized cost-effectiveness.
Insights
Fixed-dose empagliflozin/metformin combination therapy offers improved glycemic control for type 2 diabetes patients. This combination therapy is well-tolerated, reduces pill burden, and enhances patient adherence.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes often requires combination therapy due to monotherapy limitations.
- Sodium glucose co-transporter 2 (SGLT2) inhibitors offer glucose control independent of beta-cell function with low hypoglycemia risk.
- Fixed-dose combination tablets can improve patient adherence by reducing pill burden.
Purpose of the Study:
- To review the clinical efficacy and tolerability of empagliflozin/metformin combination therapy for type 2 diabetes.
- To discuss the benefits of fixed-dose empagliflozin/metformin tablets.
Main Methods:
- Review of available literature on empagliflozin/metformin combination therapy.
- Discussion of clinical trial data regarding efficacy and tolerability.
- Consideration of bioequivalence studies for fixed-dose formulations.
Main Results:
- Empagliflozin/metformin combination significantly improves glycemic control, body weight, and blood pressure.
- The combination therapy is associated with a low risk of hypoglycemia.
- Fixed-dose tablets demonstrate bioequivalence and potential for improved adherence and cost-effectiveness.
Conclusions:
- Empagliflozin/metformin combination therapy is an effective treatment option for type 2 diabetes.
- Fixed-dose empagliflozin/metformin tablets offer advantages in adherence and potentially cost-effectiveness.
- This combination represents a valuable therapeutic strategy for managing type 2 diabetes.
